Professor John-Michael Sauer is a Professor Practice in Law at Arizona Law, an Adjunct Research Professor at the College of Medicine, and a Senior Vice President at the Critical Path Institute. Prior to joining the Critical Path Institute, Professor Sauer was at Eli Lilly where he participated in the development, registration, and commercialization of Strattera for the treatment of ADHD in children and adults, as well as supported many other discovery and development teams. He also played a pivotal leadership role in the transformation of Elan Pharmaceutical’s discovery and development strategies including the incorporation of several quantitative translational science approaches. He has over 20 years of experience in drug discovery and development and is dedicated to bringing quantitative translational science approaches to safety assessment, as well as transforming nonclinical safety data to drive clinical study design and data interpretation. Professor Sauer has scientific publications in the areas of toxicology, drug metabolism, clinical pharmacology, pharmacokinetics, and pharmacology. He received his undergraduate and Master’s degree in Biomedical Sciences at Western Michigan University and his Doctorate degree in Pharmacology and Toxicology from University of Arizona.
Professor Sauer teaches LAW 576A Drug Discovery, Development & Innovation to Reach the Marketplace during Fall term.